SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A-Reference-Cited by-同舟云学术

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

Published:2019-11-28 Issue:1 Volume:26 Page:47-55
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Tiede Andreas¹^ORCID,Allen Geoffrey²^ORCID,Bauer Alexander³,Chowdary Pratima⁴^ORCID,Collins Peter⁵,Goldstein Brahm²,Jiang Hongyu Jeanne²,Kӧck Kathleen⁶,Takács István⁷,Timofeeva Margarita⁸,Wolfsegger Martin³,Srivastava Shouryadeep²

Affiliation:

1. Hannover Medical School Hannover Germany

2. Baxalta US Inc, a member of the Takeda group of companies Cambridge MA USA

3. Baxalta Innovations GmbH, a member of the Takeda group of companies Vienna Austria

4. Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK

5. Institute of Infection and Immunity School of Medicine Cardiff University Cardiff UK

6. IQVIA Overland Park KS USA

7. Semmelweis University Budapest Hungary

8. Federal State Budgetary Institution of Science “Kirov Scientific and Research Institute of Hematology and Blood Transfusion of Federal Medico‐Biological Agency” Kirov Russian Federation

Funder

Baxalta

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13878

Reference28 articles.

1. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children

2. World Federation of Hemophilia.Guidelines for the management of hemophilia.https://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed November 15 2017.

3. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

4. A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

5. Half-life extended factor VIII for the treatment of hemophilia A

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin’s lymphoma;Journal of Nanobiotechnology;2024-08-10

2. Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma;Research and Practice in Thrombosis and Haemostasis;2024-01

3. A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future;Pharmaceutics;2023-02-10

4. Selective human factor VIII activity measurement after analytical in‐line purification;Research and Practice in Thrombosis and Haemostasis;2022-10

5. Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma;Acta Biomaterialia;2022-09